COMP <GO>
CLGN vs BBLG // EV/EBITDA & P/E VALUATION
CollPlant Biotechnologies Ltd (NASDAQ) VS. Bone Biologics Corp (NASDAQ) • 15-METRIC TALLY: CLGN 3
— BBLG 0
■ METRIC PARITY
LAST: $4.14 (-6.02%) • MKT CAP: $12.7M
valuation
—
LAST: $0.38 (-2.03%) • MKT CAP: $1.3M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CLGN VS. BBLG)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CLGN | BBLG | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.80% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 3/9 | +2.00 | CLGN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.3 | 31.7 | +28.60 | CLGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $12.7M | $1.3M | $11.4M | CLGN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CLGN REV | BBLG REV | CLGN GROSS % | BBLG GROSS % | CLGN FCF | BBLG FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.4M | $0 | 64.8% | — | -$9.4M | -$2.7M |
| FY 2024 | $515.0K | $0 | -50.0% | — | -$14.6M | -$4.1M |
| FY 2023 | $11.0M | $0 | — | — | -$2.8M | -$9.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CLGN // BETA —
BBLG // BETA —